Re Dickinson Investment Advisors, LLC Lineage Cell Therapeutics, Inc. Transaction History
Re Dickinson Investment Advisors, LLC
- $1.77 Billion
- Q4 2024
A detailed history of Re Dickinson Investment Advisors, LLC transactions in Lineage Cell Therapeutics, Inc. stock. As of the latest transaction made, Re Dickinson Investment Advisors, LLC holds 205 shares of LCTX stock, worth $139. This represents 0.0% of its overall portfolio holdings.
Number of Shares
205Holding current value
$139% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding LCTX
# of Institutions
134Shares Held
106MCall Options Held
22.1KPut Options Held
0-
Broadwood Capital Inc New York, NY41.7MShares$28.3 Million1.65% of portfolio
-
Black Rock Inc. New York, NY9.56MShares$6.5 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.63MShares$5.87 Million0.0% of portfolio
-
Perceptive Advisors LLC New York, NY7.24MShares$4.92 Million0.12% of portfolio
-
Defender Capital, Llc.5.96MShares$4.06 Million1.17% of portfolio
About Lineage Cell Therapeutics, Inc.
- Ticker LCTX
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 169,755,008
- Market Cap $115M
- Description
- Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-re...